145 related articles for article (PubMed ID: 35650135)
1. A Bone Histomorphometric Analysis of Hypophosphatasia-related Osteoporosis after Teriparatide Treatment.
Mizuno H; Sawa N; Sekine A; Inoue N; Oba Y; Ikuma D; Yamanouchi M; Hasegawa E; Suwabe T; Suzuki H; Hoshino J; Ubara Y
Intern Med; 2023 Jan; 62(1):75-79. PubMed ID: 35650135
[TBL] [Abstract][Full Text] [Related]
2. ADULT HYPOPHOSPHATASIA TREATED WITH TERIPARATIDE: REPORT OF 2 PATIENTS AND REVIEW OF THE LITERATURE.
Camacho PM; Mazhari AM; Wilczynski C; Kadanoff R; Mumm S; Whyte MP
Endocr Pract; 2016 Aug; 22(8):941-50. PubMed ID: 27042741
[TBL] [Abstract][Full Text] [Related]
3. Teriparatide treatment in an adult patient with hypophosphatasia exposed to bisphosphonate and revealed by bilateral atypical fractures.
Righetti M; Wach J; Desmarchelier R; Coury F
Joint Bone Spine; 2018 May; 85(3):365-367. PubMed ID: 29246529
[TBL] [Abstract][Full Text] [Related]
4. Treatment of adult hypophosphatasia with teriparatide.
Camacho PM; Painter S; Kadanoff R
Endocr Pract; 2008 Mar; 14(2):204-8. PubMed ID: 18308659
[TBL] [Abstract][Full Text] [Related]
5. Lack of sustained response to teriparatide in a patient with adult hypophosphatasia.
Gagnon C; Sims NA; Mumm S; McAuley SA; Jung C; Poulton IJ; Ng KW; Ebeling PR
J Clin Endocrinol Metab; 2010 Mar; 95(3):1007-12. PubMed ID: 20089612
[TBL] [Abstract][Full Text] [Related]
6. Adult hypophosphatasia treated with teriparatide.
Whyte MP; Mumm S; Deal C
J Clin Endocrinol Metab; 2007 Apr; 92(4):1203-8. PubMed ID: 17213282
[TBL] [Abstract][Full Text] [Related]
7. Adult hypophosphatasia treated with reduced frequency of teriparatide dosing.
Polyzos SA; Tournis S; Goulas A; Kollia P; Whyte MP
J Musculoskelet Neuronal Interact; 2021 Dec; 21(4):584-589. PubMed ID: 34854399
[TBL] [Abstract][Full Text] [Related]
8. A low serum alkaline phosphatase may signal hypophosphatasia in osteoporosis clinic patients.
Ng E; Ashkar C; Seeman E; Schneider HG; Nguyen H; Ebeling PR; Sztal-Mazer S
Osteoporos Int; 2023 Feb; 34(2):327-337. PubMed ID: 36434431
[TBL] [Abstract][Full Text] [Related]
9. Extremely elevated serum alkaline phosphatase level upon treatment with teriparatide: a case report.
Javinani A; Aghaei Meybodi HR; Kavosi H
J Med Case Rep; 2020 Jul; 14(1):87. PubMed ID: 32616027
[TBL] [Abstract][Full Text] [Related]
10. Teriparatide or alendronate in glucocorticoid-induced osteoporosis.
Saag KG; Shane E; Boonen S; Marín F; Donley DW; Taylor KA; Dalsky GP; Marcus R
N Engl J Med; 2007 Nov; 357(20):2028-39. PubMed ID: 18003959
[TBL] [Abstract][Full Text] [Related]
11. Effect of osteoporosis medication on changes in bone mineral density and bone turnover markers after 24-month administration of daily teriparatide: comparison among minodronate, raloxifene, and eldecalcitol.
Nakatoh S
J Bone Miner Metab; 2018 Mar; 36(2):221-228. PubMed ID: 28293779
[TBL] [Abstract][Full Text] [Related]
12. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status.
Langdahl BL; Marin F; Shane E; Dobnig H; Zanchetta JR; Maricic M; Krohn K; See K; Warner MR
Osteoporos Int; 2009 Dec; 20(12):2095-104. PubMed ID: 19350340
[TBL] [Abstract][Full Text] [Related]
13. Teriparatide vs. alendronate as a treatment for osteoporosis: changes in biochemical markers of bone turnover, BMD and quality of life.
Panico A; Lupoli GA; Marciello F; Lupoli R; Cacciapuoti M; Martinelli A; Granieri L; Iacono D; Lupoli G
Med Sci Monit; 2011 Aug; 17(8):CR442-448. PubMed ID: 21804463
[TBL] [Abstract][Full Text] [Related]
14. Impact of bisphosphonate wash-out prior to teriparatide therapy in clinical practice.
Keel C; Kraenzlin ME; Kraenzlin CA; Müller B; Meier C
J Bone Miner Metab; 2010; 28(1):68-76. PubMed ID: 19633810
[TBL] [Abstract][Full Text] [Related]
15. Effects of Teriparatide and Sequential Minodronate on Lumbar Spine Bone Mineral Density and Microarchitecture in Osteoporosis.
Miyaoka D; Imanishi Y; Ohara M; Hayashi N; Nagata Y; Yamada S; Mori K; Emoto M; Inaba M
Calcif Tissue Int; 2017 Oct; 101(4):396-403. PubMed ID: 28589205
[TBL] [Abstract][Full Text] [Related]
16. Bisphosphonate-associated atypical sub-trochanteric femur fractures: paired bone biopsy quantitative histomorphometry before and after teriparatide administration.
Miller PD; McCarthy EF
Semin Arthritis Rheum; 2015 Apr; 44(5):477-482. PubMed ID: 25312241
[TBL] [Abstract][Full Text] [Related]
17. 24-Month Open-Label Teriparatide Once-Weekly Efficacy Research Trial Examining Bone Mineral Density in Subjects with Primary Osteoporosis and High Fracture Risk.
Sugimoto T; Shiraki M; Fukunaga M; Hagino H; Sone T; Nakano T; Kishimoto H; Ito M; Yoshikawa H; Kishida M; Irie C; Nakamura T
Adv Ther; 2017 Jul; 34(7):1727-1740. PubMed ID: 28631217
[TBL] [Abstract][Full Text] [Related]
18. Trabecular Bone Score in Patients With Chronic Glucocorticoid Therapy-Induced Osteoporosis Treated With Alendronate or Teriparatide.
Saag KG; Agnusdei D; Hans D; Kohlmeier LA; Krohn KD; Leib ES; MacLaughlin EJ; Alam J; Simonelli C; Taylor KA; Marcus R
Arthritis Rheumatol; 2016 Sep; 68(9):2122-8. PubMed ID: 27111239
[TBL] [Abstract][Full Text] [Related]
19. Teriparatide Treatment in Patients With WNT1 or PLS3 Mutation-Related Early-Onset Osteoporosis: A Pilot Study.
Välimäki VV; Mäkitie O; Pereira R; Laine C; Wesseling-Perry K; Määttä J; Kirjavainen M; Viljakainen H; Välimäki MJ
J Clin Endocrinol Metab; 2017 Feb; 102(2):535-544. PubMed ID: 27732335
[TBL] [Abstract][Full Text] [Related]
20. Bone mineral density and fracture risk in adult patients with hypophosphatasia.
Genest F; Claußen L; Rak D; Seefried L
Osteoporos Int; 2021 Feb; 32(2):377-385. PubMed ID: 32879991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
